Table 1 Baseline clinical characteristics
Variable | nal-IRI plus 5-FU/LV (n = 51) |
|---|---|
Age | |
Median (Range) | 67 (50–78) |
Gender | |
Male | 30 (58.8%) |
Female | 21 (41.2%) |
Pancreatic tumor location | |
Head | 19 (37.3%) |
Body | 18 (35.3%) |
Tail | 14 (27.4%) |
Disease status at start of nal-IRI | |
Recurrent | 9 (17.6%) |
Initially Metastatic | 42 (82.4%) |
Baseline CA 19–9 level | |
Within normal range (< 40 U/mL) | 9 (17.6%) |
Above normal range (≥40 U/mL) | 42 (82.4%) |
Site of metastatic lesions | |
Liver | 41 (80.4%) |
Lung | 16 (31.4%) |
Lymph node, Distant | 16 (31.4%) |
Peritoneum | 15 (29.4%) |
Bone | 7 (13.7%) |
Measurable metastatic sites | |
1 | 19 (37.3%) |
2 | 24 (47.0%) |
≥ 3 | 8 (15.7%) |
Previous radiotherapy | 8 (15.7%) |
Previous surgery | 12 (23.5%) |
Previous lines of palliative chemotherapy | |
1 | 40 (78.4%) |
2 | 11 (21.6%) |
Previous first-line palliative chemotherapy | |
Gemcitabine plus nab-paclitaxel | 48 (94.1%) |
Gemcitabine monotherapy | 3 (5.9%) |
Previous irinotecan containing chemotherapy | 1 (2.0%) |
Previous 5-FU/LV containing chemotherapy | 13 (25.5%) |